EP
JANX icon

Essential Partners’s Janux Therapeutics JANX Stock Holding History

Essential Partners’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.07K Buy
+70
New +$1.01K ﹤0.01% 2217
2025
Q3 		– Sell
-44
Closed -$1.02K – 2733
2025
Q2 		$1.02K Buy
+44
New +$1.16K ﹤0.01% 1512

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Essential Partners's JANX Position: Q2 2026 in Review

Essential Partners opened a new position in Janux Therapeutics (JANX) in Q2 2026: 70 shares worth $1.07K. The stake represents ﹤0.01% of the portfolio and ranks #2217 among its holdings. This is a return to the name: Essential Partners previously reported a position in JANX as recently as Q2 2025.

Essential Partners first reported a position in JANX in Q2 2025 and has held it in 2 quarters since. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Essential Partners held 70 shares of Janux Therapeutics worth $1.07K as of Q2 2026.
  • Janux Therapeutics was a new Essential Partners position in Q2 2026.
  • Janux Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2217 holding.
  • Essential Partners first reported a position in Janux Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.